Tris Pharma, a South Brunswick specialty pharmaceutical company, said its generics business has launched the first generic alternative to treat attention deficit hyperactivity disorder as well as narcolepsy.
The liquid product, called Dextroamphetamine Sulfate oral solution, also is the first generic to be launched by Tris under its new generic pharmaceuticals business.
"This is a big milestone for us," said Janet Penner, president of Tris Pharma's generics business.
Penner said the generics business was formed in June to market and distribute Tris Pharma's own products. Previously, the company contracted with other companies to market its drugs. Penner said the division has more approved generics in the pipeline and plans to introduce additional drugs this year.
Previously: Tris names president of generics division
Tris Pharma received approval from the Food and Drug Administration on May 29 to sell its solution, the generic equivalent to ProCentra, a drug made by Outlook Pharmaceuticals Inc. and sold by FSC Pediatrics.
ADHD is a common disorder childhood disorder than can continue through adolescence and adulthood, according to the National Institute of Mental Health. Symptoms include difficulty staying focused, difficulty controlling behavior and hyperactivity. Narcolepsy is characterized by extreme tendency to fall asleep when in relaxed surroundings.
Tris Pharma employs more than 300 and reports more than $100 million in annual revenue.
Reporter Tom Zanki is @BizTZanki on Twitter.